Community Magazine
A Mythical magical Mix of Creatures: A Chimera
Today I learned that my chimerism test in my peripheral blood was 100% host and 0% donor.
This test measure the percent of my blood cells, specifically that are from me and from Yaakov who generously gave his hematopoietic stem cells in a effort to cure my cancer a little over 8 years ago.
While this result was hardly a surprise as my last test over 6 years ago in my bone marrow was 3% donor and 0% of the important T cells.
And we all knew that transplant failed years ago because I rejected the graft.
It us now clearly documented that I am no longer chimeric. Remember that a chimera is a mix of two animals. I am just me- not a trace of Yaakov in my bloodstream.
Some 8 years ago, I was, for a brief hopeful few months, both Brian and Yaakov, hoping to become 100% Yaakov in my blood, with the real chance that his healthy immune system would kill on my cancer forever. That I would be cured.
Sadly, that was not to be and I lost the graft and relapsed. That story and my subsequent challenges in controlling my CLL is the genesis and the guts of this blog.
Now that era is officially closed. I did the test as there are some cases of donor chimerism climbing when patients take ibrutinib.
The news makes me a tiny bit sad. It reminds of a more optimistic time when I thought I might be able to forever say goodbye to CLL. While I still harbor that hope, it is tempered with heavy dose of realism.
I will be forever grateful to Yaakov for his generous and selfless gift of a chance to save to my life.
SaveSaveIf you want a personal response, or just want to stay in touch, please email me at [email protected]. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.
Author's Latest Articles
-
A Matching-Adjusted Indirect Comparison of Acalabrutinib Vs. Zanubrutinib in Relapsed Or Refractory CLL
-
My Personal Decision to Restart My CLL (chronic Lymphocytic Leukemia) Treatment
-
ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials
-
Dr. Stephan Stilgenbauer on the Evolution of CLL to Richter’s Syndrome from ASH 2022